--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results-- SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (CAPR) (NASDAQ ...
Milestone represents a significant step forward in the development of deramiocel for the treatment of Duchenne muscular dystrophy in the European region SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- ...
Capricor Therapeutics announced positive results from the four-year HOPE-2 Open-Label Extension study for their lead cell therapy candidate, Deramiocel, aimed at treating Duchenne Muscular Dystrophy ...
Capricor Therapeutics Inc. CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor’s stock surged more ...
Late-breaking presentation at MDA to feature Phase 3 HOPE-3 results supporting Deramiocel in Duchenne muscular ...
FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review process Company expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO, Jan.
–Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development– The publication, ...
SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...
SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results